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sUmmARy – Vancomycin-resistant enterococci (VRe), especially Enterococcus faecium, have 
emerged as significant nosocomial pathogens and patients with impaired host defenses are at a par-
ticular risk of VRe infection. The most common occurrence is asymptomatic colonization of the 
gastrointestinal tract that can persist for a long time and serve as a reservoir for transmission of VRe 
to other patients. We present a case of a patient who was diagnosed with acute myelogenous leukemia 
and suffered from bone marrow aplasia following induction therapy. The patient received prolonged 
broad-spectrum antimicrobial therapy. during hospital stay, the patient developed clostridium difficile 
infection (Cdi) and was found to be colonized with a strain of Enterococcus faecium resistant to van-
comycin during therapy for Cdi. This case also highlights the role of risk factors that could contribute 
to development of resistance, particularly Cdi. early detection of VRe colonization or infection is a 
crucial component in hospital program designed to prevent transmission of nosocomial infections. 
surveillance cultures of such patients should be mandatory.
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Introduction
enterococci resistant to vancomycin have emerged 
as the leading cause of nosocomial infections world-
wide. in an effort to prevent the spread of vancomycin 
resistance, Centers for disease Control and preven-
tion have recommended periodical culture surveys of 
stool and rectal swabs, depending on the risk popula-
tion and hospital units involved1. Therefore, this 
screening has been found to be effective in detecting 
vancomycin-resistant enterococci (VRe)2,3. However, 
the widespread use of glycopeptides in hospitals has 
led to the emergence of VRe, which account for ap-
proximately 30% of all enterococcal infections, with 
the majority of VRe isolates (>90%) being Enterococ-
cus (E.) faecium4. some investigators have reported the 
overall prevalence of VRe in europe to range from 
1.5% to 8.6%5,6. in the United states, the prevalence of 
VRe on admission to an intensive care unit has been 
reported to range from 12% to 43%7. The reported 
rates of VRe colonization in hospitalized patients 
vary, ranging from 1.5% to 32%5,6,8. The risk factors for 
nosocomial VRe colonization or infection include ad-
vanced age, prolonged hospital stay, interhospital 
transfer, prolonged duration of antibiotic treatment 
(especially with vancomycin and cephalosporins), dif-
ferent surgical procedures and presence of immuno-
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compromised state9,10. patients with clostridium diffi-
cile infection (Cdi) are considered to be at a greater 
risk of becoming colonized with VRe, probably be-
cause of the common risk factors involved11. Cdi is 
also common in hematologic patients, with the inci-
dence rate ranging from 4.8% to 9% in patients with 
acute myelogenous leukemia, from 4.9% to 7.5% in 
patients undergoing autologous and from 14% to 
30.4% in those undergoing allogeneic hematopoietic 
stem cell transplantation (HsCt)12-15.
This report presents a case of a patient with acute 
myelogenous leukemia following induction therapy, 
whose surveillance rectal and throat swabs yielded E. 
faecium resistant to vancomycin, Vana phenotype.
Case Report
in march 2015, a 48-year-old female patient was 
admitted for the first time to the department of He-
matology because of fever and spontaneous gingival 
bleeding. during the previous year, she was taking an-
tibiotic treatment several times due to recurrent uri-
nary tract infection (Uti). two weeks before this ad-
mission, she was treated with peroral cefuroxime be-
cause of suspected pyelonephritis. After finishing the 
antibiotic treatment prescribed, laboratory findings 
showed leukocytosis (39.3x109/L) and trombocytope-
nia (82x109/L) with blasts detected in peripheral blood 
(17%), so she was hospitalized for further treatment.
on day 2 of her hospital stay, urine culture yielded 
Klebsiella pneumoniae >105 colony forming units (CfU/
mL), with a significantly lowered leukocyte count after 
treatment for Uti. However, further clinical findings 
revealed acute myelogenous leukemia, with no chro-
mosome 16 inversion detected by fluorescent in situ 
hybridization technique. following induction therapy, 
the patient suffered from bone marrow aplasia accom-
panied by febrility and increase in C-reactive protein 
level (256.7 mg/L). due to development of fever in 
granulocytopenia, and based on the clinical picture, du-
ration and degree of granulocytopenia, monotherapy 
with a beta-lactam with activity against Pseudomonas 
aeruginosa was first started, combined with other gram-
negative and gram-positive agents, for suspicion of 
possible infection caused by resistant gram-negative or 
gram-positive bacteria. Therefore, further therapy in-
cluded piperacillin/tazobactam (3x4.5 g i.v. daily for 4 
days), meropenem (3x1 g i.v. daily for 17 days), then 
amikacin (2x500 mg i.v. daily for 8 days), vancomycin 
(2x1 g i.v. daily for 10 days) and imipenem (3x1 g i.v. 
daily for 10 days). As our patient was at a high risk of 
developing fungal infection, empirical antifungal ther-
apy with amphotericin B was also administered. The 
patient became afebrile from day 30. After 40 days of 
hospital stay, the patient was discharged with no pro-
phylactic antibiotic therapy.
one week after discharge, in April, the patient was 
readmitted to the department of Hematology for fur-
ther chemotherapy. from that time on, she was clini-
cally stable, afebrile, with periods of bone marrow 
aplasia, so multiple transfusions of red blood cells and 
platelets were administered. on day 7, she started hav-
ing profuse watery diarrhea, up to 10 times, which was 
clinically indicative of clostridium (c.) difficile infec-
tion, and a stool sample was taken and sent for detec-
tion of c. difficile toxin. on the same day, after c. dif-
ficile toxin was detected, peroral treatment with vanco-
mycin was initiated at a dose of 2.5 mL 4 times a day 
for 10 days.
The patient had negative surveillance cultures upon 
admission (initial screening). However, in order to ex-
clude possible colonization with multidrug-resistant 
hospital pathogens, surveillance cultures should be 
taken on at least three consecutive occasions, one week 
or more apart16. Therefore, another surveillance throat 
swab was obtained on day 10 and yielded E. faecium 
resistant to vancomycin. on day 15 of admission, she 
became febrile (38.4 °C), so blood culture was taken 
and Klebsiella pneumoniae was grown. At that time, 
meropenem was added to therapy at a dose of 1 g i.v. 
every 8 hours. surveillance rectal swab was taken on 
day 19 for detection of multidrug-resistant hospital 
pathogens (vancomycin-resistant enterococci, VRe; 
multidrug-resistant acinetobacter baumannii, mRAB; 
carbapenem-resistant Enterobacteriaceae, CRe; ex-
tended spectrum beta-lactamase producing gram-neg-
ative bacilli, esBL) and E. faecium resistant to vanco-
mycin was isolated.
The strain was sent to dr fran mihaljević Univer-
sity Hospital for infectious diseases in Zagreb, and 
polymerase chain reaction (pCR) assay confirmed the 
Vana phenotype of vancomycin resistance.
Microbiology
Rectal swab was inoculated on CHRomagar VRe 
plate, a chromogenic medium for detection of Vana/
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VanB phenotype of vancomycin resistance in Entero-
cocci (CHRomagar, paris, france). on the first day of 
subculture at 37 °C, pink to mauve colonies were re-
vealed (after 24 h). The grown isolate was confirmed as 
E. faecium using automated Vitek 2 system (biomer-
ieux, marcy-l’etoile, france).
Throat swab was inoculated on blood agar and 
shiny, γ (gamma)-hemolytic colonies were observed 
after 24 hours of incubation with further identification 
being identical as described above.
Antimicrobial susceptibility testing was first done 
using Kirby-Bauer disk-diffusion method and con-
firmed by determining minimum inhibitory concen-
tration (miC) values using Vitek 2 automated meth-
od. The strain was shown to be resistant to ampicillin 
(miC ≥32 µg/mL), vancomycin (miC ≥32 µg/mL) 
and teicoplanin (miC ≥32 µg/mL), but susceptible to 
linezolid (miC 2 µg/mL) and tigecycline (miC ≤0.12 
µg/mL), having a Vana specific phenotype of vanco-
mycin resistance confirmed by pCR assay.
stool sample was tested according to two-step al-
gorithm guidelines of the european society of Clini-
cal microbiology and infectious disease and a toxi-
genic strain of c. difficile was detected using a confir-
matory molecular test17.
Discussion
enterococci resistant to vancomycin were first de-
tected in england in 198818. VRe, especially E. faeci-
um, is a significant nosocomial pathogen and presents 
a serious threat to immunocompromised patients. 
Compared to strains of E. faecalis, E. faecium displays a 
higher degree of resistance to multiple antibiotics, in-
cluding ampicillin, gentamicin, ciprofloxacin, vanco-
mycin and teicoplanin19. Therefore, it is important to 
identify the enterococcal strain to the species level. 
enterococci belong to the fourth most common noso-
comial pathogens in intensive care units, with VRe 
accounting for 28.5% of enterococcal isolates20. inva-
sive VRe infections have been associated with high 
morbidity and mortality rates21,22. studies found crude 
mortality rates to range from 17% to 100%, with a 
mortality rate of 73% in patients with hematologic 
malignancies23-25. There are studies showing VRe in-
fection to be a strong predictor of mortality in liver 
transplant patients, with a mortality rate of 46% in 
liver transplant recipients with VRe bacteremia26,27. it 
has been suggested that VRe infections and coloniza-
tion may be a reflection of a complicated medical 
course, and those patients have therefore been at a 
higher risk of dying, which could contribute to high 
mortality rates. Asymptomatic VRe colonization is of 
particular interest as it can persist for a long period and 
serve as a reservoir for transmission of VRe or present 
a source of possible infection. Thus, it is important to 
perform active surveillance (screening) of patients, es-
pecially those in intensive care units and hemato-on-
cology wards9,10. many studies also showed correlation 
between VRe colonization and treatment with certain 
antimicrobial agents such as metronidazole, second- 
and third-generation cephalosporins, aminoglycosides 
and vancomycin28,29.
in our case, the patient was on a prolonged broad-
spectrum antimicrobial therapy during her first hospi-
talization (meropenem, piperacillin/tazobactam, then 
amikacin, vancomycin and imipenem/cilastatin), 
which was continued with meropenem and vancomy-
cin during second hospitalization. she was also immu-
nosuppressed because of her hematologic disease, 
which has been identified as an independent risk fac-
tor for acquiring VRe30. developing diarrhea in our 
patient could have also increased the likelihood of 
colonization with VRe, as proposed in a study by falk 
et al.31. prolonged hospital stay could have also con-
tributed in our case. due to bone marrow aplasia, she 
was isolated in a hematologic sterile unit. All the risk 
factors mentioned could have triggered the develop-
ment of resistance, especially prolonged therapy with 
vancomycin, which is more likely to promote coloniza-
tion and transmission of VRe by selection pressure. As 
the E. faecium strain resistant to vancomycin was iso-
lated from surveillance throat and rectal swabs, with 
no clinical and laboratory markers of infection, we de-
tected gastrointestinal VRe colonization. most VRe 
colonized patients remain colonized for a long period. 
montecalvo et al. showed a 7-week persistence of gas-
trointestinal VRe colonization in adult patients hos-
pitalized on oncology ward32.
There are studies that indicate a correlation be-
tween c. difficile infection and gastrointestinal VRe 
colonization, possibly because of the common risk fac-
tors including prolonged broad-spectrum antimicro-
bial therapy, extended hospital stay and underlying im-
munocompromised state10. in this way, c. difficile in-
fection could be a possible predictor for developing 
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VRe associated infection or colonization due to simi-
lar patient risk profile33,34. our patient had both c. dif-
ficile infection and VRe colonization, which could be 
explained by the risk factors mentioned above.
Results of some studies indicate the possibility of 
VRe screening by using stools sent for c. difficile toxin 
analysis, as the results are comparable to screening us-
ing separately taken stool specimens or rectal swabs11,35. 
This is also less invasive and might be less of a problem 
in neutropenic patients for whom rectal swabs are 
sometimes a concern35. However, all these promising 
results could potentially lead to in-hospital screening 
using stools sent for c. difficile toxin analysis as a rea-
sonable surrogate for screening individual high-risk 
patients, with substantial cost savings35.
Although up to now six phenotypes of vancomycin 
resistance have been described in enterococci, the 
Vana and VanB phenotypes are clinically significant 
and mediated by transferable operons. The VanA phe-
notype is almost always plasmid-mediated, raising the 
possibility of horizontal transfer of resistance36.
By using measures of active screening of patients, 
we successfully detected VRe Vana phenotype in our 
institution, emphasizing their importance and contin-
uous implementation, especially in high-risk patients. 
According to the last available data provided by the 
Croatian Committee for Antibiotic Resistance sur-
veillance in 2013 on the three-month follow-up (oc-
tober 1 to december 31), 5% of E. faecium strains re-
sistant to vancomycin were isolated37.
performing special surveillance cultures of patients 
to detect gastrointestinal colonization should be con-
sidered as an essential component of successful VRe 
control programs. obtaining periodic stool or rectal 
specimens from high-risk patients such as those in in-
tensive care units, hematology-oncology wards or 
transplantation units should be mandatory. surveil-
lance cultures should be taken upon admission and 
twice weekly thereafter, and should be inoculated on 
appropriate selective media for detecting VRe16,38.
in conclusion, early detection of VRe colonization 
or infection is a crucial component of hospital pro-
gram designed to prevent nosocomial infections. 
Quick information from microbiology laboratory is 
the first line of defense against the intrahospital spread 
of VRe. prompt and correct identification of entero-
cocci and detection of vancomycin resistance are es-
sential in detection of VRe colonization or infection, 
in order to avoid complex and costly procedures re-
quired when the problem is delayed.
Active screening accompanied by infection control 
measures is crucial in the prevention of VRe transmis-
sion. Rational use of antibiotics is also a helpful pre-
ventive measure against the development of antimi-
crobial resistance.
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sažetak
KoLoniZACiJA VAnKomiCin ReZistentnom BAKteRiJom EntErococcus faEcium  
i clostridium difficilE infeKCiJA U HemAtoLošKe BoLesniCe
i. Goić-Barišić, m. radić, a. novak, Ž. rubić, n. Boban, B. lukšić i m. tonkić
Vankomicin-rezistentni enterokoki (VRe), naročito Enterococcus faecium, spadaju među najznačajnije bolničke patogene, 
pri čemu su naročito ugroženi bolesnici oslabljenog imunosnog statusa. pritom je najčešća pojava asimptomatske koloniza-
cije probavnog sustava koja može ustrajati duže vremena i biti rezervoar za širenje VRe na ostale bolesnike. donosimo prikaz 
slučaja bolesnice s dijagnozom akutne mijelomonocitne leukemije praćene aplazijom koštane srži nakon indukcijske terapije. 
Bolesnica je liječena antibioticima širokog spektra. tijekom hospitalizacije u bolesnice se razvila infekcija bakterijom clostri-
dium difficile (Cdi) uz dokazanu kolonizaciju sojem Enterococcus faecium rezistentnog na vankomicin tijekom terapije zbog 
Cdi. također su prikazani čimbenici rizika koji su u navedenom slučaju mogli poslužiti kao potencijalni okidač za razvoj 
rezistencije, s osobitim naglaskom na Cdi. Rano otkrivanje kolonizacije ili infekcije navedenim sojevima je iznimno znača-
jan čimbenik bolničkog programa za prevenciju širenja bolničkih infekcija. mikrobiološki nadzor uzimanjem nadzornih 
kultura mora biti obvezni dio protokola pri hospitalizaciji takvih bolesnika.
Ključne riječi: akutna mijelomonocitna leukemija; clostridium difficile; Enterococcus faecium; Vankomicin-rezistentni enterokok
